AR043823A1 - Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen - Google Patents

Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen

Info

Publication number
AR043823A1
AR043823A1 ARP040101103A ARP040101103A AR043823A1 AR 043823 A1 AR043823 A1 AR 043823A1 AR P040101103 A ARP040101103 A AR P040101103A AR P040101103 A ARP040101103 A AR P040101103A AR 043823 A1 AR043823 A1 AR 043823A1
Authority
AR
Argentina
Prior art keywords
alkyl
preparation
compounds derived
oxima
manufacture
Prior art date
Application number
ARP040101103A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR043823A1 publication Critical patent/AR043823A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos derivados de oxima, sus sales farmacéuticamente aceptables así como sus formas enantioméricas, sus diastereoisómeros y sus racematos; la obtención de los compuestos recién mencionados, los medicamentos que los contienen y su fabricación así como el uso de los compuestos recién mencionados como inhibidores de desacetilasa de histona (HDAC), para la inhibición del crecimiento tumoral o el tratamiento del cáncer, o para la fabricación de los medicamentos correspondientes. Reivindicación 1: Un compuesto de la fórmula (1) en la que R1 es H o alquilo C1-4; R2 es arilo, heteroarilo o heterociclilo; todos ellos pueden estar opcionalmente sustituidos una o varias veces con alquilo; halógeno; -O-alquilo; -NH(alquilo); -N(alquilo)2; o R1 y R2 junto con el átomo de C al que están unidos forman un hidrocarburo cíclico; y sales farmacéuticamente aceptables del mismo.
ARP040101103A 2003-04-04 2004-04-01 Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen AR043823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03007829 2003-04-04

Publications (1)

Publication Number Publication Date
AR043823A1 true AR043823A1 (es) 2005-08-17

Family

ID=33104054

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101103A AR043823A1 (es) 2003-04-04 2004-04-01 Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen

Country Status (14)

Country Link
US (1) US7173060B2 (es)
EP (1) EP1613622A1 (es)
JP (1) JP2006515345A (es)
KR (1) KR100733757B1 (es)
CN (1) CN1771247A (es)
AR (1) AR043823A1 (es)
AU (1) AU2004226215A1 (es)
BR (1) BRPI0409182A (es)
CA (1) CA2519301A1 (es)
CL (1) CL2004000732A1 (es)
MX (1) MXPA05010424A (es)
RU (1) RU2005133994A (es)
TW (1) TW200424187A (es)
WO (1) WO2004087693A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4725944B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤
NZ534831A (en) 2002-03-13 2007-01-26 Janssen Pharmaceutica Nv Carbonylamino-derivatives having histone deacetylase (HDAC) inhibiting enzymatic activity
DE60321667D1 (en) 2002-03-13 2008-07-31 Janssen Pharmaceutica Nv Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase
NZ534771A (en) 2002-03-13 2006-04-28 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
MX2007001120A (es) 2004-07-28 2007-03-15 Janssen Pharmaceutica Nv Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa.
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
US8835501B2 (en) 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
AU2007206950B2 (en) 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
DK1979328T3 (da) 2006-01-19 2013-03-25 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CN101374828B (zh) 2006-01-19 2012-09-19 詹森药业有限公司 作为组蛋白脱乙酰酶抑制剂的杂环烷基衍生物
JP5137848B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
JP5225104B2 (ja) 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
CA2680838A1 (en) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitory effect as active ingredient
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
EP2268611A2 (en) * 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2828524C (en) 2011-02-28 2020-01-07 Repligen Corporation Histone deacetylase inhibitors
NZ711585A (en) 2013-03-15 2020-05-29 Biomarin Pharm Inc Hdac inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1033046B (it) 1970-10-31 1979-07-10 Finotto Martino Procedimento di fabbricazione di benzimidazoli sostituiti
DE2201062A1 (de) 1972-01-11 1973-07-26 Bayer Ag N-alkoxycarbonyl- bzw. n-alkylthiocarbonyl-2-(2'-thienyl)-benzimidazole, ein verfahren zu ihrer herstellung und ihre verwendung als fungizide
NZ219974A (en) 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
JPH0692398B2 (ja) * 1987-07-07 1994-11-16 日本農薬株式会社 ピラゾ−ルオキシム誘導体及び該化合物を含有する殺菌殺虫殺ダニ剤
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
JP4641670B2 (ja) * 2001-06-28 2011-03-02 株式会社フジタ 水浄化構造
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos

Also Published As

Publication number Publication date
EP1613622A1 (en) 2006-01-11
CL2004000732A1 (es) 2005-02-04
RU2005133994A (ru) 2006-06-27
KR20060011947A (ko) 2006-02-06
TW200424187A (en) 2004-11-16
AU2004226215A1 (en) 2004-10-14
CA2519301A1 (en) 2004-10-14
MXPA05010424A (es) 2005-11-04
BRPI0409182A (pt) 2006-04-11
JP2006515345A (ja) 2006-05-25
KR100733757B1 (ko) 2007-06-29
CN1771247A (zh) 2006-05-10
WO2004087693A1 (en) 2004-10-14
US7173060B2 (en) 2007-02-06
US20040214880A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
AR043823A1 (es) Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
CO2021003298A2 (es) Compuestos de sulfonamidaurea novedosos
CY1122933T1 (el) Ενωσεις θειαζολοκαρβοξαμιδιων και πυριδινοκαρβοξαμιδιου χρησιμες ως αναστολεις κινασης ριμ
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
AR065876A1 (es) Compuestos activos para 11 beta -hsd1
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
EA201490445A1 (ru) Циклопропанаминовое соединение
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
EA201070523A1 (ru) Производные фталазинона
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR057162A1 (es) Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac)
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
JP2013509392A5 (es)
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
AR066972A1 (es) Derivados azapeptidicos
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
PE20040913A1 (es) Enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico como inhibidores de desacetilasa histona (hdac)
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal